| gap-pubmed-20260410- | How does CR2-Crry selectivity affect therapeutic efficacy versus systemic comple | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What downstream mechanisms link C3 inhibition to improved motor and visual funct | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What is the causal relationship between cardiolipin enhancement and mitochondria | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does GRB2 mechanistically link ginsenoside Rg3 to cardiolipin homeostasis re | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What drives the connection between sleep disturbance and stress-induced kynureni | open | 0.74 | 0.00 | 2026-04-10 | 0 | | stress-neurobiology |
| gap-pubmed-20260410- | How can metabolomic biomarkers overcome participant heterogeneity to achieve dia | open | 0.76 | 0.00 | 2026-04-10 | 0 | | biomarker-development |
| gap-pubmed-20260410- | What mechanisms link kynurenine pathway activation to ADHD neurotransmitter dysr | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurotransmitter-systems |
| gap-pubmed-20260410- | What clinical trial designs can validate vitamin D's neuroprotective effects acr | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does vitamin D's regulation of intestinal microbiota mechanistically contrib | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neuropsychiatry |
| gap-pubmed-20260410- | What are the specific molecular mechanisms by which vitamin D receptors in glial | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does Syncrip's regulation of Notch signaling integrate with other temporal p | open | 0.70 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | What are the specific molecular components of the stabilization complexes recrui | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | How do pathogenic human Syncrip mutations specifically disrupt phase separation | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodevelopment |
| gap-pubmed-20260410- | Does Hippo pathway activation represent a therapeutic target or harmful interven | open | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link MST1 activation to huntingtin pathology in Huntington's dis | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do therapeutic strategies targeting humoral immunity compare in efficacy for | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What are the precise molecular mechanisms by which AQP4-specific antibodies and | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does AMPK coordinate hypothalamic feeding circuits with circadian metabolic | open | 0.71 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the molecular mechanisms by which AMPK regulates neuronal membrane exci | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do UCH-mediated ubiquitination imbalances differentially drive cancer versus | open | 0.86 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What molecular mechanisms underlie the inverse association between cancer and ne | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do distinct microglial subsets differentially contribute to synaptic loss ve | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines whether protective CD11c+ microglia transition to inflammation-p | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | Which of the 70+ LOAD genetic variants are actually disease-relevant versus stat | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the functional mechanisms by which LOAD genetic risk variants contribut | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What determines the specificity of FUS chaperone activity for TAZ versus other c | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does FUS loss-of-function in TAZ regulation contribute to ALS/FTD pathogenes | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do R406W homozygotes show earlier onset and more behavioral symptoms compare | open | 0.74 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms drive tau deposition initiation specifically in ventromedial tem | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do R406W patients show predominant 4R tauopathy unlike previous reports, and | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does the temporal relationship between dopamine transporter loss and substan | open | 0.72 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms explain preserved dopamine transporter binding in Alzheimer's an | resolved | 0.73 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why do variable sequences in STOP proteins differ completely among species despi | open | 0.68 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How do STOP protein defects mechanistically cause synaptic dysfunction and behav | open | 0.85 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | What molecular mechanisms underlie STOP proteins' microtubule cold-stabilization | open | 0.80 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |
| gap-pubmed-20260410- | How do disease stage, insult type, and cellular damage load determine optimal au | open | 0.79 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does rilmenidine show opposite effects in cell culture versus mouse models o | open | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Under what physiological conditions is PINK1-Parkin mitophagy activated in livin | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What are the systemic consequences of therapeutically targeting APOE4 given its | resolved | 0.83 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link APOE4's enhanced peripheral immune function to brain neuroi | resolved | 0.82 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | How does APOE4's beneficial immune function reconcile with its established role | partially_addressed | 0.89 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Does MED's anti-inflammatory effect translate to neuroprotection in actual neuro | resolved | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What downstream mechanisms explain MED's selective inhibition of ERK1/2 but not | open | 0.80 | 0.00 | 2026-04-10 | 0 | | neuroinflammation |
| gap-pubmed-20260410- | What is the mechanistic intersection between ataxin-3's DUB function and gene tr | open | 0.78 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How does polyglutamine expansion specifically alter ataxin-3's deubiquitinating | open | 0.85 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | Why does MTNR1A rs2119882 association with acne only emerge in night shift worke | open | 0.73 | 0.00 | 2026-04-10 | 0 | | circadian-neurobiology |
| gap-pubmed-20260410- | What molecular mechanisms link CLOCK rs1801260 polymorphisms to increased acne s | open | 0.77 | 0.00 | 2026-04-10 | 0 | | circadian-neurobiology |
| gap-pubmed-20260410- | Why does NfL correlate with cognitive but not motor decline in Parkinson's disea | open | 0.76 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | What mechanisms link neurofilament light chain release to cognitive decline in P | resolved | 0.80 | 0.00 | 2026-04-10 | 0 | | neurodegeneration |
| gap-pubmed-20260410- | How do homeostatic mechanisms prevent synaptic saturation during bidirectional p | open | 0.73 | 0.00 | 2026-04-10 | 0 | | synaptic-biology |